Fig 2: The association between ANXA4 and NF-?B p50 expression on the survival time of patients with ovarian clear cell carcinoma. Kaplan-Meier survival analysis demonstrated that high expression levels of ANXA4 and NF-?B p50 were independent risk factors for overall survival. ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.

Fig 3: Expression levels of ANXA4, NF-?B p50 and mutant p53 in ovarian clear cell carcinoma tissues (magnification ×400). ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.

Fig 4: Nuclear expression of ANXA4 and NF-?B p50 in different ovarian tissues. Immunohistochemistry was performed to detect ANXA4 and NF-?B p50 expression in normal ovarian tissues and tissues from different subtypes of ovarian cancer (magnification ×400). OCCC, ovarian clear cell carcinoma; ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells.

Fig 5: Effects of ANXA4 and NF-?B p50 on cell proliferation and apoptosis. (A) Expression changes of Cyclin D1 and Bcl-2 in ES-2 cells before and after transfection of the ANXA4 gene, and addition of the NF-?B inhibitor. (B) Proliferation capacity of ES-2 cells before and after addition of the NF-?B inhibitor, detected via the MTT assay. (C) Apoptosis of ES-2 cells before and after addition of the NF-?B inhibitor, detected via Annexin V-APC/PI double-staining. *P<0.05. ANXA4, Annexin IV; NF-?B, nuclear factor-?-light-chain-enhancer of activated B cells; Bcl-2, B-cell lymphoma 2. *ES-2 compared with ES-2-A4-O; #ES-2-A4-O compared with ES-2-A4-O + BAY 11-2078.